FOLIA BIOLOGICA, published by Charles University Prague, First Faculty of Medicine, is an esteemed academic journal that has been contributing to the fields of Biochemistry, Cell Biology, Developmental Biology, Genetics, Immunology, and Molecular Biology since its inception in 1961. With an ISSN of 0015-5500, this journal serves as a vital platform for researchers and professionals to disseminate their findings and advance knowledge within these disciplines. Despite its current Category Quartiles ranking in the lower tiers (Q3 and Q4), FOLIA BIOLOGICA continues to provide valued insights and foster scholarly dialogue, particularly in its paralleled fields. The journal is headquartered in Prague, Czech Republic, and operates without Open Access options, which emphasizes its focus on curated, peer-reviewed content essential for academicians and students. By bridging theoretical and practical knowledge, FOLIA BIOLOGICA remains committed to enriching the scientific community and serving as a cornerstone for future research innovations.

GENETICS AND MOLECULAR BIOLOGY, published by the SOC BRASIL GENETICA, is a prominent journal dedicated to the advancement of knowledge in the fields of genetics and molecular biology. Since its inception in 1998, this Open Access journal has served as a vital platform for researchers, professionals, and students to disseminate their findings and engage with the latest innovations and discoveries. With an impact factor that reflects its growing influence, GENETICS AND MOLECULAR BIOLOGY ranks in the Q3 category for both genetics and molecular biology as of 2023, indicating its position within the academic community. The journal is indexed in Scopus, highlighting its commitment to maintaining rigorous peer-review standards while providing wide-reaching access to quality research. Operating out of Ribeirão Preto, Brazil, it fosters a collaborative environment for academic discourse and research development not only in Brazil but also globally. The journal encourages submissions that explore a wide range of topics in genetics and molecular biology, making it an essential resource for anyone involved in these dynamic fields.

Epigenetics, published by Taylor & Francis Inc, is a leading journal in the fields of Cancer Research, Medicine (miscellaneous), and Molecular Biology. With an ISSN of 1559-2294 and an E-ISSN of 1559-2308, this journal has been paving the way for groundbreaking research since its inception in 2006, and it continues to play a crucial role in advancing our understanding of epigenetic mechanisms and their implications in health and disease. The journal is highly regarded, ranking in the Q1 category for Medicine and Q2 for both Cancer Research and Molecular Biology according to the 2023 category quartiles. Researchers and professionals in the field will find invaluable insights and innovative studies within its pages, making it an essential resource for those engaged in cutting-edge research. Although the journal is not open access, it encourages a comprehensive understanding through high-quality peer-reviewed content. With its creative exploration of the epigenetic landscape, Epigenetics serves as a vital platform for the sharing of knowledge that could lead to breakthroughs in treatments and therapies.

Clinical Epigenetics is a pioneering open-access journal published by BMC, dedicated to advancing the field of epigenetics and its critical implications in clinical and translational research. Established in 2011, the journal has become an authoritative resource in the realms of developmental biology, genetics, and molecular biology, as evidenced by its impressive 2023 Scopus categorization as a Q1 journal in multiple domains including clinical genetics. With a robust impact factor and rankings that place it among the top quartiles in its fields—Rank #13 in Clinical Genetics and #14 in Developmental Biology—Clinical Epigenetics serves as an essential platform for researchers, professionals, and students alike, encouraging the dissemination of high-quality research findings. Operating from its United Kingdom headquarters, this journal not only contributes to scholarly dialogue across the globe but also supports unrestricted access to vital findings that push the boundaries of our understanding of epigenetic mechanisms and their clinical applications.

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, published by Elsevier, stands as a premier journal in the fields of Genetics and Health, Toxicology and Mutagenesis, boasting a Q1 ranking in both categories for 2023. With an impressive impact factor and rigorous peer-review process, this journal serves as a vital platform for disseminating cutting-edge research and comprehensive reviews regarding the implications of genetic mutations and related health effects. Established in the Netherlands, it has evolved from its inception in the early 1990s to become an essential resource for researchers, professionals, and students alike, facilitating advancements in the understanding of mutation research. Despite not offering an open-access model, the journal ensures a wide reach through institutional subscriptions, emphasizing its commitment to fostering scholarly dialogue and promoting significant findings within the scientific community.

The Journal of Developmental Origins of Health and Disease is a premier academic publication under the esteemed Cambridge University Press, dedicated to advancing the understanding of how developmental processes influence health outcomes across the lifespan. With an ISSN of 2040-1744 and an E-ISSN of 2040-1752, this journal has established itself as a critical resource in the field of medicine, currently positioned in the Q2 category of Medicine (miscellaneous). Having converged from 2010 to 2024, this journal reflects a significant commitment to exploring the interconnections between early development and subsequent health conditions. Ranked 147 out of 398 in its category according to Scopus, it retains a commendable 63rd percentile status, highlighting its contributions to this rapidly evolving field. Though it does not offer open access, the journal remains a vital platform for researchers, professionals, and students interested in uncovering the intricate links between developmental biology and public health challenges.

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

Chemical Research in Toxicology is a premier journal published by the American Chemical Society, dedicated to advancing the understanding of toxicological effects associated with chemical substances. Since its inception in 1988, this esteemed journal has maintained a robust impact factor, ranking in the Q1 quartile for both Medicine (miscellaneous) and Toxicology as of 2023, reflecting its significance and influence in the fields of pharmacology and toxicology. With an impressive Scopus ranking at #16 out of 133 in the Toxicology category, it serves as a vital resource for researchers, professionals, and students seeking cutting-edge insights and scholarly articles that bridge the gap between chemistry and toxicological science. Although not an open-access publication, it continues to provide comprehensive analyses and original research that inform safe chemical practices and regulatory policies, further enhancing its role in public health and safety.

Drug and Chemical Toxicology is a well-respected journal in the fields of toxicology, pharmacology, and public health, published by Taylor & Francis Ltd. Since its inception in 1978, this journal has diligently explored the effects and mechanisms of chemical exposures on health and the environment, fulfilling a crucial role in advancing scientific understanding and safeguarding public health. The journal is indexed across prestigious databases and features an impressive array of articles categorized within the Q2 and Q3 quartiles across various categories in 2023, reflecting its significance in Chemical Health and Safety as well as Environmental and Occupational Health disciplines. With an extensive reach and a focus on interdisciplinary research, Drug and Chemical Toxicology offers a rich repository of original research, reviews, and methodological advancements, catering to a diverse audience of researchers, professionals, and students dedicated to the betterment of safety and health standards. Although not an open-access publication, its articles are widely accessible to the academic community, ensuring that critical innovations and insights are shared for the greater good.

Human Gene is an innovative open access journal published by ELSEVIER, dedicated to the ever-evolving field of genetics. Established in 2022, this journal serves as a vital resource for researchers, professionals, and students alike, aiming to facilitate the dissemination of groundbreaking research and advancements in both basic and clinical genetics. With an ISSN of 2773-0441, Human Gene focuses on providing a platform for high-quality studies that investigate genetic mechanisms, their implications in health and disease, and novel therapeutic strategies. The journal currently holds a Q4 ranking in both Genetics and Clinical Genetics categories, reflecting its emerging status within the scientific community, and strives to enhance its impact to better serve an engaged audience. With its base in Amsterdam, Netherlands, Human Gene is committed to making research accessible through its open access model, inviting contributions that advance our understanding of human genetics and foster collaboration across disciplines.